Clinical Trials Browser

Phase 2 × Completed × Neoplasms, Squamous Cell × Clear all

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Penile Neoplasms, Vulvar Neoplasms, Neoplasms, Squamous Cell

NCT01581970 2019-09-11

Potentiation of Cetuximab by Tregs Depletion With CSA in Advanced Head & Neck Cancer

Phase 2 Completed

7 enrolled 9 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Neoplasms, Squamous Cell

NCT00661427 2018-01-11

Cetuximab at Either 500 or 750 mg/m2 Every Other Week for Recurrent or Metastatic Head and Neck Squamous Cell Cancer

Phase 2 Completed

61 enrolled 8 charts

Head & Neck

Head and Neck Neoplasms, Neoplasms, Squamous Cell

NCT00229723 2009-08-04

IRESSA™ (Gefitinib) With Cisplatin Plus Radiotherapy for the Treatment of Previously Untreated Unresected Late Stage III/IV Non-Metastatic Head and Neck Squamous Cell Carcinoma

Phase 2 Completed

224 enrolled 21 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Neoplasms, Squamous Cell

NCT00255476 2009-04-23

The IRESSA Novel Head and Neck Chemotherapy Evaluation Study

Phase 2 Completed

64 enrolled

Head & Neck

Head and Neck Neoplasms, Neoplasms, Squamous Cell

Clinical Trials

PEVOsq

Potentiation of Cetuximab by Tregs Depletion With CSA in Advanced Head & Neck Cancer

Cetuximab at Either 500 or 750 mg/m2 Every Other Week for Recurrent or Metastatic Head and Neck Squamous Cell Cancer

IRESSA™ (Gefitinib) With Cisplatin Plus Radiotherapy for the Treatment of Previously Untreated Unresected Late Stage III/IV Non-Metastatic Head and Neck Squamous Cell Carcinoma

The IRESSA Novel Head and Neck Chemotherapy Evaluation Study